Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
Executive Summary
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
You may also be interested in...
Gamida Cell’s Bone Marrow Transplant Alternative Succeeds In Phase III
The Novartis-backed company will begin a rolling submission to the US FDA for its cord blood-derived cell therapy omidubicel in Q4 based on improved engraftment versus standard cord blood.
Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019
Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.